Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

BeiGene Collaborates with InnoRNA to Develop mRNA Therapeutics

publication date: Jul 8, 2022

Beijing BeiGene formed a global strategic collaboration with Shenzhen’s InnoRNA to develop mRNA therapeutics. InnoRNA uses its LNP (liquid nanoparticle) delivery technology and mRNA drug discovery program to discover novel mRNA candidates. InnoRNA will receive an upfront cash payment and will be eligible to receive milestones and royalties on sales. BeiGene will hold exclusive global development and commercialization rights for the collaboration’s mRNA-LNP therapies. InnoRNA will receive an additional upfront cash payment and milestones for granting BeiGene a non-exclusive license to its proprietary LNP Technology platform. More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160; SHA: 688235)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital